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Survival Differences by Sex for Patients with Advanced
Non-small Cell Lung Cancer on Eastern Cooperative
Oncology Group Trial 1594
Heather A. Wakelee, MD,* Wei Wang, PhD,† Joan H. Schiller, MD,‡ Corey J. Langer, MD,§
Alan B. Sandler, MD, Chandra P. Belani, MD,¶ and David H. Johnson, MD
for the Eastern Cooperative Oncology Group
Introduction: Previous data suggest that women may live longer
with advanced non-small cell lung cancer (NSCLC) than men. We
evaluated whether sex affected survival in the Eastern Cooperative
Oncology Group (ECOG) E1594 trial. E1594 randomized patients
with advanced NSCLC to one of four platinum doublets and found
that all four regimens had comparable efficacy.
Patients and Methods: Patients in the E1594 database were divided
into male and female cohorts; response and survival were calculated
separately for each cohort. Known prognostic factors and differ-
ences in toxicity profiles were compared between the two cohorts.
Results: All 1157 eligible patients (431 women, 726 men) from
E1594 were included in this analysis. There was no statistically
significant difference in performance status, weight loss of 10%,
stage, or incidence of brain metastases between women and men.
Response rates were similar (19% for both; P  0.15). The median
survival time for women, however, was significantly longer at 9.2
months (95% CI, 8.1–10.4 months) versus only 7.3 months for men
(95% CI, 6.8–8.0 months) (P  0.004 log-rank test). Toxicity was
generally greater in women than in men.
Conclusions: Women in ECOG 1594 had a 1.9-month statistically
significant improvement in median survival compared with men,
despite similar response rates and greater toxicity and no difference
in other known prognostic factors. These data strongly support the
significance of sex as a separate prognostic factor in advanced
NSCLC and emphasize the importance of sex as a stratification
factor in future phase III NSCLC trials.
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Lung cancer is the leading cause of cancer death in bothmen and women, responsible for more deaths annually
than breast, prostate, and colon cancers combined.1 Observa-
tions that women with NSCLC seemed to experience better
survival than men were first published in the 1970s.2 Popu-
lation-based studies support this hypothesis, including an
analysis of more than 20,000 lung cancer cases from Poland
that found a relative risk (RR) of death for men of 1.15 (P 
0.001) in multivariate analysis.3 An evaluation of 4618
NSCLC patients who were prospectively enrolled and fol-
lowed from 1997 to 2002 at the Mayo Clinic in Rochester,
Minnesota found a relative risk for mortality in men of 1.20
(95% confidence interval 1.11–1.30) after adjusting for age,
histology, stage, smoking history, and treatment.4
In early-stage NSCLC, most trials have shown a trend
toward superior outcome for women versus men. Female sex
was one of only two significant independent positive prog-
nostic factors for survival on multivariate analysis of 351
patients who underwent potentially curative resection for
NSCLC at a single Norwegian hospital between 1988 and
2002.5 Other surgical series have also demonstrated trends of
improved survival for women, but statistical significance was
lost in most multivariate analyses.6–8 For patients with early-
stage NCSLC treated with radiation therapy on Radiation
Therapy Oncology Group (RTOG) protocols, a retrospective
review of nearly 2000 patients treated between 1983 and
1994 found that median survival for women was 11 months
versus 10 months for men.9
In advanced-stage NSCLC, there have been several
evaluations of gender differences in survival, all retrospec-
tive. In an earlier analysis of Eastern Cooperative Oncology
Group (ECOG) data from seven randomized phase III trials
(n  893), the 1-year survival rate for women with advanced
NSCLC was 26% versus 16% for men.10 In multivariate
analysis, this difference remained significant with a P value
of 0.005. When Albain et al.11 grouped the data from 13
SWOG trials (more than 2500 patients) between 1974 and
1988, female sex was a strong independent factor for im-
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proved survival with a risk ratio of 1.3 (P  0.00005), but
this significance was lost in a smaller, more thorough evalu-
ation, that included multiple other factors such as laboratory
values. The European Lung Cancer Working Party (ELCWP)
evaluated more than 1000 patients treated between 1980 and
1991 for either locally advanced or advanced-stage NSCLC
and found female sex to be one of several variables associated
with improved survival with a relative risk of death of 0.7
(P  0.03) in multivariate analysis.12 O’Connell et al.13 also
noted female sex to be one of four predictors of improved
survival among 378 patients with advanced-staged NCSLC
treated with chemotherapy from 1978 to 1986 at a single
cancer center. In multivariate analysis, the median survival
time (MST) for women was 12.4 months versus 8.8 months
for men (P  0.001).
Large trials among uniform populations addressing the
role of sex on survival in NSCLC are extremely limited in the
literature. Most large randomized trials cannot be pooled
because of survival differences in the different arms. Because
of a lack of survival difference among the four arms of ECOG
1594 (E1594), we had a unique opportunity to examine the
sex effect on survival in a population of nearly 1200 patients
with similarly staged and treated advanced NSCLC.
PATIENTS AND METHODS
E1594 enrolled 1207 patients (of whom 1157 were
eligible) with stage IIIB (with malignant effusion) or IV
NSCLC, and randomized them to one of four different che-
motherapy treatment arms.14 The reference regimen, arm A,
consisted of paclitaxel and cisplatin. Arms B, C, and D
consisted of cisplatin/gemcitabine, cisplatin/docetaxel, and
carboplatin/paclitaxel, respectively. All arms used 3-week
cycles, except arm B, which used a 4-week cycle. Patients
were stratified for performance status (PS; 0-1 vs 2); weight
loss in the previous 6 months; disease stage; and presence or
absence of brain metastases. No prior chemotherapy or bio-
logical therapy was allowed. All patients gave informed
consent. Standard ECOG response criteria were used.14
Survival time was calculated from the date of registra-
tion to date of death; patients who were alive were censored
at the date last known alive. Time to progression was calcu-
lated from the date of registration to date of progression or
death without progression; patients who were alive and re-
lapse-free were censored at the date of last known follow-up.
Patients were entered into this study between October 1996
and May 1999. The median survival for all 1207 patients was
8 months. No differences among any of the arms in response
rates (RR), overall survival (OS), or time to progression
(TTP) were observed when the data were analyzed by eligible
versus all randomized patients.14
Because the RR, TTP, and OS were identical among the
four arms of the study, all patients could be grouped together
and divided into female/male cohorts. After validating the
significance of several known prognostic factors for the entire
population, the cohorts were compared for differences in
known prognostic factors, including PS, weight loss, stage,
and presence of brain metastases. Histology was also com-
pared. RRs were calculated separately for each cohort and
compared using a 2 test. PFS and OS were calculated
separately for each cohort using the methods of Kaplan and
Meier and were compared with each other using log rank
tests. Cox proportional hazards models were applied to study
the effects of PS, weight loss 10%, presence of brain
metastases, and stage (IIIB vs IV) on PFS and OS. Survival
by sex for each of the four chemotherapy arms of E1594 was
evaluated. Finally, toxicity differences by sex cohort were
compared.
RESULTS
We divided the population of 1157 eligible patients
from E1594 into female (431 patients, 37%) and male (726
patients, 63%) cohorts. No significant differences were seen
between the cohorts with regard to PS, weight loss 10%,
stage (IIIB vs IV), or presence of brain metastases (Table 1).
Men were more likely to have weight loss (65% for men vs
58% for women; P  0.02) and be slightly older (mean age
61.9 years vs 60.5 years for women; P 0.02). Women were
more likely to have adenocarcinoma histology (63% of
women vs 53% of men; P  0.003).
Our analysis of outcome predictors for the entire E1594
population validated the importance of PS, weight loss
10%, and presence of brain metastases, but not histology
(adenocarcinoma versus squamous cell carcinoma), on out-
come. For the entire patient population, the MST for those
with an ECOG PS of 0 was 10.8 months (95% CI, 9.6–11.7
months) versus 7.1 months (95% CI, 6.6–7.7 months) and 3.9
months (95% CI, 3.0–7.0 months) for those with PS of 1 and
2, respectively (P  0.0001). MST for patients with no
weight loss before study entry was 9.5 months (95% CI,
8.7–10.7 months) versus 4.9 months (95% CI, 4.3–6.6
months) for those with weight loss of 10%, (P  0.0001).
Those with no brain metastases had a MST of 8.1 months
(95% CI, 7.4–8.8 months) versus 7.2 months (95% CI,
6.7–8.4 months) for those with brain metastases (P  0.03).
No difference in MST was found for those with adenocarci-
noma versus squamous cell histology (P  0.47).
There was no difference in RR by sex (19% in both
cohorts; P  0.15) (Table 2). However, both PFS and MST
were different by sex. Median PFS for women was 3.8
months (95% CI, 3.6–4.3 months) versus 3.5 months (95%
CI, 3.0–3.8 months) for men (P 0.022) (Table 2 and Figure
TABLE 1. Patient characteristics from ECOG 1594
Women Men P value
N  1157 (eligible) 431 (37%) 726 (63%)
ECOG PS 0/1/2 (%) 33/60/7 29/66/5 0.07
Any weight loss (%) 58 65 0.02
Weight loss 10% (%) 10 13 0.09
Mean age (yr) 60.5 (59.6–61.4) 61.9 (61.2–62.6) 0.02
% IIIB 14 13 0.57
Brain metastases (%) 14 12 0.19
Adeno/squamous
histology (%)
63/14 53/23 0.003/0.006
ECOG, Eastern Cooperative Oncology Group; PS, performance status
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1). MST was also better for women (9.2 months; 95% CI,
8.1–10.4 months) than men (7.3 months; 95% CI, 6.8–8.0
months) (P  0.004) (Table 2 and Figure 2). This difference
in MST translated into differences in percentages of patients
alive at 1, 2, and 3 years. For women, these were 38%, 14%,
and 7%, respectively, versus 31%, 11%, and 5%, respec-
tively, for men. The survival difference remained statistically
significant after adjusting for PS, weight loss 10%, pres-
ence of brain metastases, and stage of cancer (IIIB versus IV).
In a Cox proportional hazards model to predict sur-
vival, the following factors persisted as important prognostic
factors; sex, performance status (2 vs 0 or 1), weight loss
(10% vs 10%), and stage. The hazard ratio for women
versus men was 0.84 (95% CI, 0.74–0.94). The other pre-
dictors all had negative impact on survival with hazard ratios
of 1.52 (95% CI, 1.17–1.96) for performance status, 1.44
(95% CI, 1.20–1.73) for weight loss, and 1.20 (95%CI,
1.01–1.43) for stage.
No difference in survival was found by regimen of
chemotherapy for either of the sex cohorts (Table 3). For
women, P  0.81 by log rank test when comparing the four
different chemotherapy arms. MST ranged from 9.0 months
(95% CI, 7.0–11.6 months) for carboplatin/paclitaxel to 9.4
months (95% CI, 7.8–12.2 months) for cisplatin/gemcitabine.
For men, P  0.49 by log rank test when comparing the four
different chemotherapy arms. MST ranged from 6.7 months
(95% CI, 6.0–8.5 months) on cisplatin/docetaxel to 7.7
months (95% CI, 6.2–9.4 months) with carboplatin/pacli-
taxel.
When survival by sex was calculated separately for
each arm of the trial, the trend for improved survival in
women versus men was seen for all four arms, but statistical
significance was lost (Table 3). On arm A: cisplatin/pacli-
TABLE 2. Patient Outcomes for ECOG 1594
Women Men P value
N  1157 (eligible) 431 (37%) 726 (63%)
Censored 9 (2.1%) 9 (1.2%) 0.26
Response rate (%) 19 19 0.99
Median progression-free
survival (mo)
3.8 (3.6–4.3)
95% CI
3.5 (3.0–3.8)
95% CI
0.022
Median survival time (mo) 9.2 (8.1–10.4)
95% CI
7.3 (6.8–8.0)
95% CI
0.004
Alive at 1 yr (%) 38 31
Alive at 2/3 yr (%) 14/7 11/5
ECOG, Eastern Cooperative Oncology Group.
FIGURE 1. Progression-free survival (PFS) in months by
Kaplan-Meier analysis for female and male cohorts with ad-
vanced non-small cell lung cancer on Eastern Cooperative
Oncology Group trial 1594 (n  1157). The median PFS for
women was 3.8 months versus 3.5 months for men (P 
0.022 by log rank test).
FIGURE 2. Overall survival (OS) in months by Kaplan-Meier
analysis for female and male cohorts with advanced non-
small cell lung cancer on Eastern Cooperative Oncology
Group trial 1594 (n  1157). The median OS for women
was 9.2 months versus 7.4 months for men (P  0.004 by
log rank test).
TABLE 3. ECOG 1594 survival by arm of trial
MST (mo)Women Men P value
A: cisplatin/paclitaxel 9.2 (7.0–11.4) 7.6 (6.5–8.7) 0.089
B: cisplatin/gemcitabine 9.4 (7.8–12.2) 7.4 (6.3–8.8) 0.22
C: cisplatin/docetaxel 9.2 (7.0–11.3) 6.7 (6.0–8.5) 0.12
D: carboplatin/paclitaxel 9.0 (7.0–11.6) 7.7 (6.2–9.4) 0.19
P value 0.81 0.49
Values are median (95% confidence interval). ECOG, Eastern Cooperative Oncol-
ogy Group; MST, median survival time.
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taxel, the MST for women was 9.2 months versus 7.6 months
for men (P  0.089, log rank test). On arm B: cisplatin/
gemcitabine, the MST for women was 9.4 months versus 7.4
months for men (P  0.22). On arm C: cisplatin/docetaxel,
the MST for women was 9.2 months versus 6.7 for men (P
0.12). On arm D: carboplatin/paclitaxel, the MST for women
was 9.0 months versus 7.7 months for men (P  0.19).
Toxicity differences were identified between the gender
cohorts. In general, women tended to have more nausea,
vomiting, alopecia, neurosensory deficits, and neuropsychi-
atric deficits (Table 4). Only grade 3 cardiac toxicity was
worse in men (4.1% for women vs 7.6% for men; P  0.02).
No differences were seen for leukopenia, thrombocytopenia,
anemia, coagulation, infection, diarrhea, stomatitis, hepatic
toxicity, or hyper/hypotension. When only grade 3 toxicity
was included, women still had higher rates than men of
nausea (33% vs 20%; P  0.0001), vomiting (30% vs 18%;
P  0.0001), and neurosensory deficits (10% vs 7%; P 
0.06).
DISCUSSION
Although there have been previous evaluations of sex
differences in survival among patients with advanced
NSCLC, they are limited in that most are either large popu-
lation-based studies or retrospective analyses of multiple
trials. Our analysis is unique because of the size of the E1594
trial (nearly 1200 patients) and the final results of the study:
all arms were equivalent. Thus, we were able to divide the
entire patient population into female and male cohorts to
assess survival. This trial also incorporated modern third-
generation cytotoxic agents and included detailed toxicity
data.
The only differences in patient characteristics between
the sex-based cohorts in this analysis were in mild weight
loss, age, and histology. The difference in weight loss be-
tween the sexes may have contributed to the differences in
survival, as weight loss has been shown to be a predictor of
poor outcome.11,13,15 The weight loss difference between the
cohorts was minimal, however, and did not reach statistical
significance when weight loss of 10% was analyzed. Al-
though the men in E1594 were slightly older than women (1.4
years), age has not been shown to be an independent predictor
of outcome in NSCLC trials.10,11 Langer et al.16 conducted an
analysis of patients younger than 70 years, 70 years old, and
older than 70 years in E1594 and found no difference in
response, toxicity, or survival by age. The only other differ-
ence between the sex cohorts was in histology (percentage
with adenocarcinoma versus squamous cell carcinoma), and
histology has been shown not to be a predictor of survival,
including in this analysis.17,18 Thus, the improved survival
seen among women versus men in E1594 cannot be explained
by differences in any other known prognostic factors. There-
fore, some other explanation for the 1.9-month improvement
in MST favoring women versus men observed in this analysis
must be sought.
It is clear that there are biological differences in lung
cancer in women versus men. Women are more likely to have
adenocarcinoma than men.19,20 However, as outlined previ-
ously, this is unlikely to explain the sex-based survival
differences, as histology in this analysis and others did not
seem to be an independent predictor of survival.17,18 Molec-
ular differences have also been reported. In an analysis of 91
patients (21 women) with early-stage, resected NSCLC, high
levels of ERCC1, HER2, and RXR- were survival predic-
tors in women, but not men, whereas low COX-2 expression
and high ornithine decarboxylase expression were positive
predictors in men, but not women.21
Although differences in drug metabolism that may lead
to higher levels of cytotoxic agents in women than men may
account for the increased survival and toxicity seen in
women, the full explanation is likely to be more complicated.
One contributing factor may be differences in DNA damage
susceptibility. Women have been shown to have decreased
DNA repair capacity, which may also account for increased
lung cancer susceptibility in women.22–25 Active metabolites
that are not detoxified bind to DNA, forming DNA adducts.
Polymorphisms play a role in rates of detoxification. Wom-
en’s decreased DNA repair capacity may make them more
susceptible to both the toxic and beneficial effects of chemo-
therapy, particularly with platinum agents that work though
DNA adduct formation. Diminished DNA repair (from de-
creased ERCC1) is associated with improved outcomes in
NSCLC treated with cisplatin-based chemotherapy.26 Thus,
data that support a potential role for increased lung cancer
susceptibility for women through decreased DNA repair may
partially explain not only the increased toxicity seen in
women, but also the improved survival observed for women
treated with platinum-based therapy, such as in E1594. Hor-
monal factors may also play a role, as estrogens may lead to
proliferation of lung cancer cells and may act to form or
stabilize DNA adducts.27,28
Not all recent evaluations support the role of female sex
as a predictor of improved survival for NSCLC. All patients
(n  1053) with newly diagnosed advanced NSCLC enrolled
in nine trials (six phase II and three phase III) from 1985 and
2001 through the North Central Cancer Treatment Group
(NCCTG) were recently analyzed.29 Five of the nine trials
used a platinum agent. In multivariate analysis of overall
survival and time to progression, sex was not found to be a
significant factor (n  782), hazard ratio 0.99 (95% CI,
0.84–1.17) (P  0.92). Stage, PS, underweight body mass
index, anemia, and elevated leukocytes were significant neg-
ative predictors of survival. Toxicity differences by sex were
TABLE 4. Toxicity all grade in ECOG 1594
Women Men P value
N  1157 431 (37%) 726 (63%)
Nausea (%) 83 70 0.0001
Vomiting (%) 65 52 0.0001
Alopecia (%) 64 53 0.0003
Neurosensory (%) 49 42 0.02
Neuropsychiatric (%) 22 14 0.001
Cardiac toxicitygrade 3 (%) 4.1 7.6 0.02
ECOG, Eastern Cooperative Oncology Group.
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seen. In multivariate analysis, both grade 3 hematologic
toxicity (n  787) and non-hematologic toxicity (n  795)
were higher in women than men with odds ratios of 1.60
(95% CI, 1.14–2.26) (P  0.0007) and 1.71 (95% CI,
1.25–2.35) (P  0.001), respectively.29
Sex as a predictor of survival has also been evaluated in
the TAX326 trial, which was very similar to E1594 in both
size (more than 1200 patients) and design (compared three
different third-generation platinum-based regimens in the
first-line treatment of advanced NSCLC).30 Belani et al.31
found no overall survival advantage for women versus men
with a hazard ratio of 1.137 (P  0.18) for the 1218 patients
analyzed. Because the three arms of the study were not
equivalent, the investigators were unable to group all patients
together into female and male cohorts to evaluate survival.
Within each arm of the study, there was a trend favoring a
survival advantage for women. Statistical evaluations for
these comparisons were not reported. The median survival for
women versus men in the three arms of the trial was 12.2
versus 11.0 months, 10.8 versus 9.2 months, and 11.3 versus
9.9 months, respectively. When we analyzed sex differences
in each arm of E1594 separately, we also found survival
trends favoring women in all four arms, but statistical signif-
icance was only reached when we pooled all patients together
into female and male cohorts. As previously mentioned,
because of survival differences in the arms of TAX326, those
authors were not able to complete a similar grouped analysis.
No differences in other prognostic factors by sex reached
statistical significance in TAX326. Sex differences in toxicity
were also noted in TAX326, as in E1594. Women were more
likely than men to develop grade 3 nausea and vomiting
and neurotoxicity across all three treatment arms. Other
hematologic and non-hematologic toxicity, however, was
similar for both sexes.
Our results support the importance of the recently
opened SWOG trial S0424, an intergroup study investigating
molecular epidemiology of NSCLC in smoking and non-
smoking men and women. This study assesses the influence
of smoking, hormonal and reproductive factors, and other
exposures on sex differences in lung cancer risk. The results
of this trial should shed more light on the intriguing sex
differences seen in NSCLC.
Our study is important because it evaluates survival by
female and male cohorts in a uniform population within a
single study with nearly 1200 patients accrued. The 1.9-
month overall survival benefit for women versus men in the
absence of other prognostic factor differences or differences
in RR clearly expands the existing literature supporting a
better outcome for women with NSCLC than men with
NSCLC, despite differences in toxicity. Our results highlight
the importance of stratification by sex in future randomized
NSCLC trials. ECOG is now using gender stratification in
NSCLC trials, and we believe this stratification factor should
be adopted in all large randomized phase III trials of ad-
vanced NSCLC.
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